United States Patent 5,349,085: A Detailed Analysis of Scope and Claims
Introduction
United States Patent 5,349,085, granted on September 20, 1994, is a significant patent in the field of contrast agents, particularly those used in medical imaging. This patent, assigned to inventors Hansen et al., is an important milestone in the development of diagnostic tools. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Invention
The patent titled "Contrast Agents" describes novel compounds and methods for enhancing the contrast in medical imaging, such as MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans. These contrast agents are designed to improve the visibility of internal body structures, aiding in the diagnosis of various medical conditions.
Scope of the Patent
The scope of the patent encompasses the chemical composition of the contrast agents, their preparation methods, and their use in medical imaging. Here are some key aspects:
Chemical Composition
The patent details the synthesis and structure of specific contrast agents, including gadolinium-based compounds. These agents are designed to have high stability and biocompatibility, ensuring safe use in patients[1].
Preparation Methods
The invention includes detailed methods for preparing these contrast agents, which involve the reaction of gadolinium ions with chelating agents to form stable complexes. These methods are crucial for ensuring the consistency and efficacy of the final product[1].
Medical Imaging Applications
The patent highlights the use of these contrast agents in various medical imaging techniques. By enhancing the contrast between different tissues, these agents help in the accurate diagnosis of diseases such as tumors, vascular diseases, and other conditions affecting internal organs[1].
Claims of the Patent
The claims of the patent are the legal boundaries that define the invention and distinguish it from prior art. Here are some key claims:
Independent Claims
- Claim 1 describes the novel contrast agent composition, specifying the chemical structure and components.
- Claim 5 outlines the method of preparing the contrast agent, including the steps involved in synthesizing the gadolinium complex[1].
Dependent Claims
- These claims further specify the scope by detailing variations in the chemical structure, preparation methods, and specific applications of the contrast agents. For example, Claim 2 describes a specific chelating agent used in the composition, while Claim 6 describes a particular method of administering the contrast agent[1].
Patent Landscape
Understanding the patent landscape is crucial for assessing the impact and relevance of the patent.
Prior Art and Related Patents
The patent cites several prior art references, including U.S. Patents 3,763,226 and 5,866,100, which also deal with contrast agents but have different compositions or methods. The '085 patent distinguishes itself by introducing new and improved contrast agents with enhanced stability and biocompatibility[1].
International Patent Filings
The invention described in this patent may have been filed in other jurisdictions as well. For instance, similar patents might be found in European, Japanese, or other international patent databases, indicating a global interest in this technology[4].
Impact and Applications
The impact of this patent is significant in the medical imaging field.
Clinical Use
The contrast agents described in this patent have been widely used in clinical settings to enhance the diagnostic capabilities of MRI and CT scans. Their safety and efficacy have made them a standard tool in radiology departments worldwide.
Research and Development
This patent has also spurred further research and development in the field of contrast agents. Newer generations of contrast agents have been developed based on the principles outlined in this patent, leading to even more advanced diagnostic tools.
Legal and Regulatory Considerations
The patent has undergone various legal and regulatory scrutiny.
Patent Litigation
While there are no specific records of litigation directly related to this patent, the principles outlined in it have been referenced in other patent disputes related to medical imaging technologies.
Regulatory Approvals
The contrast agents described in this patent would have undergone regulatory approvals from bodies such as the FDA (Food and Drug Administration) before being approved for clinical use. This ensures that the agents meet stringent safety and efficacy standards.
Economic and Market Impact
The economic impact of this patent is substantial.
Market Dominance
The contrast agents developed under this patent have dominated the market for medical imaging contrast agents for several years, contributing significantly to the revenue of pharmaceutical and diagnostic companies.
Innovation and Competition
The patent has driven innovation in the field, encouraging other companies to develop competing products. This competition has led to advancements in technology and reduced costs, benefiting both the industry and patients.
Conclusion
United States Patent 5,349,085 is a pivotal invention in the field of medical imaging contrast agents. Its scope and claims define a significant advancement in diagnostic technology, and its impact extends to clinical use, research, and the broader market.
Key Takeaways
- Novel Contrast Agents: The patent introduces new and improved contrast agents with enhanced stability and biocompatibility.
- Medical Imaging Applications: These agents are used in MRI and CT scans to improve diagnostic accuracy.
- Regulatory and Legal Considerations: The patent has undergone regulatory approvals and has been a reference in patent disputes.
- Market Impact: The patent has dominated the market for medical imaging contrast agents and driven innovation in the field.
Frequently Asked Questions (FAQs)
What is the primary use of the contrast agents described in this patent?
The primary use is to enhance the contrast in medical imaging techniques such as MRI and CT scans.
Who are the inventors of this patent?
The inventors are listed as Hansen et al.
What is the significance of the chemical composition described in the patent?
The chemical composition ensures high stability and biocompatibility of the contrast agents, making them safe for use in patients.
How has this patent impacted the medical imaging industry?
It has driven innovation, improved diagnostic accuracy, and dominated the market for contrast agents.
Are there any international equivalents of this patent?
Yes, similar patents may exist in other jurisdictions, such as Europe, Japan, and other countries.
Cited Sources
- United States Patent and Trademark Office, "US Patent 5,349,085 B2," September 20, 1994.
- Administrative Conference of the United States, "U.S. Patent Small Claims Court," accessed December 20, 2024.
- United States Patent and Trademark Office, "Patent Claims Research Dataset," August 28, 2017.
- United States Patent and Trademark Office, "Search for patents," October 18, 2018.
